StockWatch
·
HomeLiveWeekly
Pharmaceuticals
Regulatory8 May 2026, 07:31 am

Biocon: Monitoring Agency Report on QIP Proceeds

AI Summary

Biocon Ltd's board reviewed the Monitoring Agency Report by India Ratings & Research for the quarter ended March 31, 2026, regarding the utilization of proceeds from Qualified Institutions Placements (QIP). The report indicates no deviation from the stated objectives. This review complies with SEBI regulations and is available on the company's website.

Key Highlights

  • Biocon's board reviewed the Monitoring Agency Report for Q1 2026.
  • India Ratings & Research found no deviation from QIP objectives.
  • Report complies with SEBI regulations.
  • Audit Committee also reviewed the report.
View BSE Filing
BIOCON
Pharmaceuticals
BIOCON LTD.

Price Impact

More from BIOCON

Acquisitions1d ago, 7:51 pm

Biocon Acquires Stake in Solar Power SPV Ampin C&I

Dividend21 May, 7:01 pm

Biocon: Reminder to Claim Unclaimed Dividends by August 20, 2026

Regulatory11 May, 8:35 am

Biocon Pharma Gets Health Canada Nod for Micafungin Injection

More in Regulatory

BHARATWIRE1d ago, 5:41 pm

Bharat Wire Ropes Receives MPCB Notice for Stoppage of Activities

CANFINHOME1d ago, 5:11 pm

Can Fin Homes Files ALM Statement for March 31, 2026

MEDPLUS1d ago, 4:41 pm

Medplus Subsidiary's Drug License Suspended for 2 Days